Logo image of ENSC

ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis

NASDAQ:ENSC - Nasdaq - US2936024056 - Common Stock - Currency: USD

5.4  -0.23 (-4.09%)

After market: 6.1409 +0.74 (+13.72%)

Fundamental Rating

3

ENSC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. The financial health of ENSC is average, but there are quite some concerns on its profitability. ENSC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ENSC has reported negative net income.
In the past year ENSC has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ENSC reported negative net income in multiple years.
In the past 5 years ENSC always reported negative operating cash flow.
ENSC Yearly Net Income VS EBIT VS OCF VS FCFENSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

ENSC has a Return On Assets of -84.47%. This is in the lower half of the industry: ENSC underperforms 70.16% of its industry peers.
ENSC's Return On Equity of -114.75% is in line compared to the rest of the industry. ENSC outperforms 41.92% of its industry peers.
Industry RankSector Rank
ROA -84.47%
ROE -114.75%
ROIC N/A
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENSC Yearly ROA, ROE, ROICENSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENSC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENSC Yearly Profit, Operating, Gross MarginsENSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

ENSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENSC has more shares outstanding
The number of shares outstanding for ENSC has been reduced compared to 5 years ago.
ENSC has a better debt/assets ratio than last year.
ENSC Yearly Shares OutstandingENSC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ENSC Yearly Total Debt VS Total AssetsENSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -18.44, we must say that ENSC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -18.44, ENSC is not doing good in the industry: 85.61% of the companies in the same industry are doing better.
ENSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.44
ROIC/WACCN/A
WACC7.95%
ENSC Yearly LT Debt VS Equity VS FCFENSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.24 indicates that ENSC has no problem at all paying its short term obligations.
ENSC's Current ratio of 3.24 is on the low side compared to the rest of the industry. ENSC is outperformed by 61.63% of its industry peers.
A Quick Ratio of 3.24 indicates that ENSC has no problem at all paying its short term obligations.
With a Quick ratio value of 3.24, ENSC is not doing good in the industry: 60.04% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
ENSC Yearly Current Assets VS Current LiabilitesENSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.46% over the past year.
The Revenue has grown by 40.36% in the past year. This is a very strong growth!
EPS 1Y (TTM)46.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%220.69%
Revenue 1Y (TTM)40.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%685.29%

3.2 Future

The Earnings Per Share is expected to grow by 163.16% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 157.05% on average over the next years. This is a very strong growth
EPS Next Y-60.41%
EPS Next 2Y-56.77%
EPS Next 3Y163.16%
EPS Next 5YN/A
Revenue Next Year107.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%

3.3 Evolution

ENSC Yearly Revenue VS EstimatesENSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ENSC Yearly EPS VS EstimatesENSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENSC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENSC Price Earnings VS Forward Price EarningsENSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENSC Per share dataENSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

ENSC's earnings are expected to grow with 163.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.77%
EPS Next 3Y163.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENSC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (2/21/2025, 8:15:50 PM)

After market: 6.1409 +0.74 (+13.72%)

5.4

-0.23 (-4.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-19 2025-03-19/amc
Inst Owners15.34%
Inst Owner Change-94.13%
Ins Owners1.17%
Ins Owner Change0%
Market Cap5.35M
Analysts82.86
Price Target53.3 (887.04%)
Short Float %4.2%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.98%
Min EPS beat(2)44.7%
Max EPS beat(2)123.26%
EPS beat(4)3
Avg EPS beat(4)38.42%
Min EPS beat(4)-54.38%
Max EPS beat(4)123.26%
EPS beat(8)7
Avg EPS beat(8)41.95%
EPS beat(12)9
Avg EPS beat(12)-139.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)600.1%
Min Revenue beat(2)-40.59%
Max Revenue beat(2)1240.78%
Revenue beat(4)2
Avg Revenue beat(4)300.74%
Min Revenue beat(4)-40.59%
Max Revenue beat(4)1240.78%
Revenue beat(8)2
Avg Revenue beat(8)138.2%
Revenue beat(12)3
Avg Revenue beat(12)80.28%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-48.77%
PT rev (3m)529.52%
EPS NQ rev (1m)-1419.44%
EPS NQ rev (3m)-876.79%
EPS NY rev (1m)33.05%
EPS NY rev (3m)-482.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)295.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)-11.87
EYN/A
EPS(NY)-13.03
Fwd EYN/A
FCF(TTM)-8.62
FCFYN/A
OCF(TTM)-8.62
OCFYN/A
SpS4.47
BVpS6.98
TBVpS6.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.47%
ROE -114.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z -18.44
F-Score4
WACC7.95%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%220.69%
EPS Next Y-60.41%
EPS Next 2Y-56.77%
EPS Next 3Y163.16%
EPS Next 5YN/A
Revenue 1Y (TTM)40.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%685.29%
Revenue Next Year107.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%
EBIT growth 1Y54.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-81.5%
EBIT Next 3Y-2.26%
EBIT Next 5Y31.23%
FCF growth 1Y53.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.49%
OCF growth 3YN/A
OCF growth 5YN/A